Grace Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Grace Therapeutics, Inc. (GRCE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.43% for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2024-08-09
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-06-30 was 4.43%.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-06-30 was 0.00%, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-09-30 was 3.20%.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-06-30 was 3.29%.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.95%, a 20.43% increase from fiscal 2023.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.28%, a 121.62% increase from fiscal 2022.
- Grace Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.48%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2024-06-30 | 4.43% 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | 3.95% 10-K · filed 2024-06-21 | |||
| 2023-12-31 | 3.95% 10-Q · filed 2024-02-12 | |||
| 2023-09-30 | 3.62% 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | 3.28% 10-K · filed 2024-06-21 | |||
| 2022-12-31 | 3.27% 10-Q · filed 2024-02-12 | |||
| 2022-09-30 | 3.20% 10-Q · filed 2022-11-14 | 3.28% 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | 3.29% 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 1.48% 10-K · filed 2023-06-23 | |||
| 2021-12-31 | 1.47% 10-Q · filed 2022-02-14 | 1.47% 10-Q · filed 2022-02-14 | ||
| 2020-12-31 | 0.00% 10-Q · filed 2022-02-14 | 0.00% 10-Q · filed 2022-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |